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Abstract 
MicroRNAs (miRNAs) are master regulators of gene expression that play key roles in 
cancer metastasis. During bone metastasis, metastatic tumor cells must rewire their 
biology and express genes that are normally expressed by bone cells (a process 
called osteomimicry), which endow tumor cells with full competence for outgrowth in 
the bone marrow. Here we establish miR-30 family members miR-30a, miR-30b, 
miR-30c, miR-30d and miR-30e as suppressors of breast cancer bone metastasis 
that regulate multiple pathways, including osteomimicry. Low expression of miR-30 in 
primary tumors from breast cancer patients were associated with poor relapse-free 
survival. Additionally, estrogen receptor (ER)-negative/progesterone receptor (PR)-
negative breast cancer cells expressed lower miR-30 levels than their ER/PR-
positive counterparts. Overexpression of miR-30 in ER/PR-negative breast cancer 
cells resulted in the reduction of bone metastasis burden in vivo. In vitro, miR-30 did 
not affect tumor cell proliferation, but did inhibit tumor cell invasion. Furthermore, 
overexpression of miR-30 restored bone homeostasis by reversing the effects of 
tumor cell-conditioned medium on osteoclastogenesis and osteoblastogenesis. A 
number of genes associated with osteoclastogenesis stimulation (IL-8, IL-11), 
osteoblastogenesis inhibition (DKK-1), tumor cell osteomimicry (RUNX2, CDH11), 
and invasiveness (CTGF, ITGA5, ITGB3) were identified as targets for repression by 
miR-30. Among these genes, silencing CDH11 or ITGA5 in ER-/PR-negative breast 
cancer cells recapitulated inhibitory effects of miR-30 on skeletal tumor burden in 
vivo. Overall, our findings provide evidence that miR-30 family members employ 
multiple mechanisms to impede breast cancer bone metastasis and may represent 
attractive targets for therapeutic intervention 
. 
Word count (limit: 250): 243  
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Introduction 
Breast cancer has a particular propensity to spread to the skeleton and around 
70-80% of patients with advanced disease develop bone metastases. Once 
metastatic cells reach the bone marrow, they alter the functions of bone-resorbing 
(osteoclasts) and bone-forming (osteoblasts) cells, promoting skeletal destruction (1). 
Anti-resorptive therapies (bisphosphonates, denosumab) are drugs that inhibit bone 
destruction (2). However, despite these treatments, a significant proportion of 
patients still experience progression of the metastatic bone disease (2). In order to 
develop more effective bone-targeted therapies, a number of genes and signaling 
pathways specifically associated with breast cancer bone metastasis came under 
intense scrutiny during the past two decades (3-5). In a similar vein, microRNAs 
(miRNAs), which are master regulators of gene expression, have emerged as key 
players in cancer progression and a whole new field of possible therapeutic 
interventions, including for bone metastasis, is coming out (6,7).  
Small non-coding miRNAs bind to target mRNAs, resulting in translational 
repression or mRNA degradation (6). MiRNAs that are frequently down-regulated in 
cancer and metastasis have been reported to act as metastasis suppressors (6). For 
example, the miR-200 family members directly target ZEB1 mRNA, a transcriptional 
repressor of the cytoskeletal rearrangement protein E-cadherin (6). As a 
consequence of miR-200 down-regulation, ZEB1 up-regulation promotes epithelial-
to-mesenchymal transition (EMT) in cancer metastasis (6). Conversely, some 
miRNAs are up-regulated in tumors, and they act as promoters of metastatic 
progression. For instance, miR-10b and miR-21 are overexpressed in cancer (6) and 
we have shown that their increased expression in breast cancer promotes tumor cell 
invasion and survival in the bone marrow, thereby facilitating bone metastasis 
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formation (8,9). Other miRNAs are emerging as important mediators of multiple 
mechanisms of bone metastasis, including cancer cell invasion (miR-31, miR-373), 
tumor±bone cell interactions (miR-34a, miR-141, miR-219) and overt skeletal 
outgrowth (miR-16, miR-204, miR-211, miR-218, miR-378, miR-379) (10,11). 
Conditioned media derived from breast and bladder carcinomas activate a miRNA 
response signature in osteoclasts that correlate with bone metastasis burden (12). 
However, the importance of miRNAs in regulating bone metastasis formation is only 
beginning to be uncovered.  
Metastatic tumor cells growing in distant organs must rewire their biology to 
meet the demands of the organ colonized, thus modifying their primary properties 
(13). In order to adapt to the bone microenvironment, we have shown that breast 
cancer cells express bone-associated genes (CTSK, SPARC, CDH11, CX43, DKK1, 
RUNX2) that are normally expressed by osteoblasts or osteoclasts. This process is 
called osteomimicry (14,15). Previous studies in bone physiology have shown that 
miR-30 family members regulate osteoblast differentiation by targeting transcription 
factor RUNX2 (16,17). Here, we hypothesized that miR-30 family members regulate 
tumor cell osteomimicry. 
The contribution of miR-30 family members in the multiple steps of bone 
metastasis formation is currently unknown. The miR-30 family consists of 5 
members: miR-30a through miR-30e. They are located at 3 different chromosomal 
regions: 1p34.2 (miR-30c and miR-30e), 6q13 (miR-30a) and 8q24.22 (miR-30b and 
miR-30d) (18). In cancer and metastasis, miR-30 family members have been 
generally ascribed a tumor suppressor role, while in some circumstances they may 
act as oncogenes (19-31). More specifically, miR-30a inhibits primary tumor growth 
and/or lung metastasis formation in several cancer types (breast, prostate, thyroid 
 6 
and colon carcinomas, osteosarcoma) (19-23). MiR-30b and miR-30c suppress in 
vivo lung metastasis of liver and colon cancer, respectively (24,25). MiR-30c also 
inhibits breast tumor chemotherapy resistance and multiple myeloma growth and is a 
predictor for clinical benefit to endocrine therapy in advanced breast cancer (26-28). 
Conversely, miR-30c was reported to promote breast cancer cell invasion in vitro 
(29). A similar oncogenic role has been reported for miR-30b/d in melanoma, by 
promoting tumor cell invasion and metastatic dissemination in vivo (30). MiR-30e 
suppresses proliferation of hepatocarcinoma cells in vitro (31).  
In this study, we provide evidence that miR-30 family members (miR-30a, 
miR-30b, miR-30c, miR-30d and miR-30e) act as tumor suppressor genes in breast 
cancer bone metastasis. We show that miR-30s overexpression in human breast 
cancer cells reduces tumor cell invasion, osteomimicry and bone destruction in vivo 
by directly targeting multiple genes.  
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Materials and Methods 
Cell lines and cell culture 
The human breast cancer lines were obtained from the American Type Culture 
Collection (ATCC) [MDA-MB-231 (year 2014), T47-D (year 2012), MCF-7 (year 
2012), BT-474 (year 2010), ZR-751 (year 2010) SK-BR3 (year 2008)] and Hs-578T 
(year 2010). The human MDA-B02 cell line (MDA-B02) is a subpopulation of the 
MDA-MB-231 breast cancer cell line that was selected for the high efficiency with 
which it metastasizes to bone in animals (32). All of these cell lines were tested for 
authentication by DNA fingerprinting using short tandem repeat (STR) method in 
2014. BC-M1 is a disseminated tumor cell (DTC) line obtained from a bone marrow 
aspirate of a breast cancer patient with no clinical signs of distant metastasis at the 
time of primary tumor resection (33,34). Cell culture conditions for growing each of 
these human breast cancer cell lines are described in the Supplementary Methods 
section. Cell cultures were routinely tested for mycoplasma by measuring the 
luminescence intensity from cell culture supernatants, using the 0\FR$OHUW3/86
Mycoplasma Detection Kit (Lonza, The Netherlands).  
 
Cohort of breast cancer patients 
Patients (n = 109) who were included in the study were free of treatment at the time 
of surgery and primary breast tumors had no inflammatory features (35). Studies 
involving human primary breast tumors were carried out according to the Declaration 
of Helsinki. Patient studies were performed after approval by an institutional review 
board (IRB) at Centre Hospitalier Lyon-Sud (CHLS, Lyon, France). The investigators 
obtained informed written consent from the subjects. Clinico-pathological 
characteristics of the cohort are shown in Supplementary Table S1 and methods for 
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the processing of patient-derived tumor tissue are described in the Supplementary 
Methods section. 
 
Plasmid constructs 
The retroviral vectors containing genomic sequences of miR-30b, miR-30d, 
miR-30b-d, miR-30b-c or miR-30a-b-c-d-e were constructed by inserting the PCR-
amplified miR-30 genomic DNA into the HindIII/EcoRI multiple cloning site (MCS) of 
pmiRVec. Genomic DNA was extracted from MDA-MB-231 with NucleoSpin® Tissue 
kit (Macherey-Nagel, Duren, Germany) and used as PCR template in presence of 
appropriate primers to generate PCR products (see Supplementary Methods 
section). The luciferase reporter plasmids were constructed by insertion of DNA 
IUDJPHQWV GHULYHG IURP WKH ¶875 RI and of the 364-base pairs of 
CDH11 ORF into the psicheck-2 dual luciferase reporter vector (Promega). The 
inserted DNA fragments were PCR-amplified from genomic MDA-MB-231, using 
appropriate primers (see Supplementary Methods section). For the construction of 
deletion mutants we used a QuikChange Lightning Site-Directed Mutagenesis Kit 
(Stratagene) with the generated psiCHECK-2 vectors, as the template, and the 
appropriated primers (see Supplementary methods). 
 
Cell transduction and transfection 
MDA-B02 cells were transduced using the pantropic retroviral expression 
packaging system (Clontech Laboratories, Takara Bio Company, CA, USA). Briefly, 
the GP2-293 cell line, which has the viral gag and pol genes incorporated in its 
genome, was transfected with the pantropic VSV-G envelope vector and the human 
miR-30 genomic DNA inserted in the retroviral pmiRVec vector (kindly provided by Dr 
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R. Agami, The Netherlands Cancer Institute, Amsterdam, NL). Virus particles were 
collected 72h after transfection, filtered and used to transduce recipient cells in 
presence of 8 Pg/mL polybrene. Transduced cells were selected with  ȝJP/
blasticidin.  
Transient overexpression or downregulation of miR-30s in MDA-B02 and 
MDA-MB-231 cells was achieved by transfecting cells with chemically modified 
double-stranded RNAs that mimic endogenous miRs (miRNA-mimics, Applied 
BioSystems) or single-stranded RNA molecules designed to specifically inhibit 
endogenous miRNAs (miRNA-inhibitors, Applied BioSystems). Both cell lines were 
transfected with 10 nM of each miR-30s mimics or antagonist sequences or with 50 
nM of negative scramble controls (Applied BioSystems). These oligonucleotides were 
incubated with 106 cells in appropriated medium, in the presence of HiPerFect 
transfection reagent (Qiagen, Courtabeuf, France) for 30 min at 37°C in a 5% C02 
incubator prior to cell plating in 6-well plates. Transfected cells were then grown in 
culture for 72 hours before cell assays. The efficiency of oligonucleotide delivery into 
these tumor cells was assessed using cell transfection with Alexa-fluor488-
conjugated oligonucleotides followed by flow cytometry analysis of fluorescently-
labeled transfected cells. HEK-293T cells were transfected with the appropriate 
reporter plasmids (see Supplementary Methods section) using X-tremeGene reagent 
(Promega). 
MC3T3-E1 osteoblastic cells were also transiently transfected by equimolar 
concentrations of each miR-30 mimic (10 nM each) or corresponding control (50 nM) 
(Applied BioSystems) by incubating cells in suspension with oligonucleotides in the 
presence of HiPerfect (Qiagen) for 30 min at 37°C prior to cell plating. 
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Hs-578T, MDA-MB-231 and MDA-B02 cells expressing luciferase2 (Hs-578T-
luc2, MDA-MB-231-luc2, MDA-B02-luc2) were obtained by retroviral transduction of 
tumor cells with pmiRVec containing the luciferase2 ORF, followed by blasticidin 
selection. Stable silencing of ITGA5 in Hs-578T-luc2 cells and of CDH11 in MDA-
B02-luc2, MDA-MB-231-luc2 and Hs-578T-luc2 cells was achieved by transducing 
these cells with lentiviral plasmids containing hairpin shRNAs targeting ITG$5 or 
CDH11. A universal non-targeting shRNA was used as a negative control (pZIP-
hCMV-shRNA-miR lentiviral vector, Transomic Technologies). shRNA designs (see 
Supplementary Methods) were predicted using the proprietary shERWOOD algorithm 
'U*UHJRU\+DQQRQ¶VODERUDWRU\DW&ROG6SULQJ+DUERU/DERUDtory) and cloned into 
the UltramiR scaffolds for optimal shRNA processing according to the constructor. 
Lentiviral particles were obtained by transfecting the Lenti-X 293T Cell Line with the 
Lenti-X HTX Packaging System and the pZIP-hCMV-shRNA plasmid in presence of 
Xfect Transfection Reagent, according to the constructor guidelines (Takara, 
Clontech Laboratories). Lentiviral particles were incubated with tumor cells seeded 
on the RetroNectin Reagent in complete medium containing tetracycline-free FBS 
(Takara, Clontech Laboratories). Transduced tumor cells were subjected to selection 
ZLWKȝJP/SXURP\FLQ 
 
Real-time RT-PCR 
Total RNA from human breast tumor and MC3T3-E1 cells was extracted using 
the Nucleospin RNA kit based on RNA adsorption on silica membranes and further 
treated by rDNAse (Macherey Nagel, Duren). Total RNA from murine osteoclasts 
was extracted with the miRNeasy Micro Kit (Qiagen) (8). cDNA was produced from 1 
µg of total RNA using the iScript cDNA Synthesis Kit (Bio-Rad). Real-time 
 11 
quantitative PCR reactions were performed using a SYBR Green qPCR kit (SYBR 
Green qPCR Super Mix, Life Technologies) on Mastercycler RealPlex (Eppendorf 
GmbH, Wesseling, Germany). Relative gene expression levels were normalized 
according to the Ct value of the gene encoding the ribosomal protein L32 and results 
were expressed as fold differences equal to 2-ǻǻ&W.  
 
Analysis of miRNA expression 
Taqman microRNA assays (Applied Biosystems, Life Technologies) were 
used to quantify miRNA and RNU48 and Snu6 levels after extraction by cell 
homogenization in Qiazol reagent followed by extraction on silica column (miRNeasy 
Micro Kit, Qiagen) (8). Ten (10) ng of total RNA were reverse-transcribed using the 
MultiScribe reverse transcriptase and 50 nM stem-loop RT primers specific for 
miRNAs and the endogenous control RNU48. Mature miRNAs were amplified using 
the TaqMan 2X universal PCR Master Mix and levels were expressed as fold 
differences equal to 2-ǻǻ&W. Analysis of miRNA expression in primary breast tumors 
was performed on TaqMan 96-well custom plates after multiplexed reverse 
transcription (RT) (Supplementary Methods section). MiRNA profiling of breast 
cancer cell lines was performed by real-time PCR on TaqMan® Low Density Array 
Human MicroRNA Panels A and B (Applied BioSystems) (See Supplementary 
Methods section). 'Ct values were calculated using RNU48 and Snu6 as 
endogenous controls with the RQ manager (Applied Biosystems). 
 
Dual luciferase reporter assay 
 HEK-293T cells were transfected by incubating the cells overnight with 10 nM 
of each miR-30s mimics or with 50 nM of negative scramble controls followed by 
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transfection with the appropriate reporter plasmids using X-tremeGene reagent 
(Promega). Forty-eight hours after transfection, cells were harvested in lysis buffer 
and subjected to luciferase reporter assay using Dual-Glo Luciferase Reporter Assay 
System (Promega). Renilla luciferase activity was normalized to corresponding firefly 
luciferase activity and plotted as a ratio between the two values. 
 
Western blotting 
Total protein cell extracts were lysed in RIPA buffer (Sigma) containing a 
cocktail of protease inhibitor (Roche). Protein cell extracts were electrophoresed on a 
4-12% gradient SDS-polyacrylamide gel (Life technologies), then transferred onto 
nitrocellulose membranes (Millipore, Billerica, MA), and proteins were probed with a 
primary antibody against CDH11 (human cadherin-11 polyclonal antibody, 1/2,000 
dilution; R&D Systems, MN, USA), ITGA5 (mouse anti-D5 integrin, 1/1,000 dilution; 
Millipore, Bedford, MA, USA), ITGB3 (D7X3P rabbit anti-integrin beta-3 monoclonal 
antibody, 1/5,000 dilution; Cell Signaling), Twinfilin-1 (rabbit polyclonal antibody, 
1/2,000 dilution; Cell Signaling), CTGF (D8Z8U rabbit monoclonal antibody, 1/2,000 
dilution; Cell Signaling), CX43 (CX43/GJA1 rabbit polyclonal antibody, 1/5,000 
dilution; Abcam), RunX2 (mouse monoclonal antibody, 1/2,000 dilution, Abcam) and 
E-tubulin (Cl B-512, 1/5,000 dilution; Sigma), according to manufactureU¶V
instructions. After incubation with primary antibodies, membranes were incubated 
with horseradish peroxide (HRP)-conjugated donkey anti-rabbit or anti-mouse 
secondary antibodies (1/2,000 dilution; Amersham), and immunostaining was 
performed with enhanced chemiluminescence (ECL) detection system (Perkin 
Elmer). 
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ELISA 
 Conditioned media from MDA-B02-Ctrl and MDA-B02-miR-30s cells were 
collected and IL-8 and IL-11 levels measured by ELISA, according to the 
PDQXIDFWXUHU¶VLQVWUXFWLRQV&OLQL6FLHQFHV 
 
Cell invasion assay 
Experiments were conducted in 24-well plates with 8-µm diameter pore-size 
inserts, previously coated with 100 µl basement membrane Matrigel (0.3 mg/mL), as 
previously described (8).  
 
Tumor cell enumeration assay  
Cell growth curves were obtained after seeding the cells (104 per well) into 12-
well plates and culturing them up to 96h. Cells were harvested with trypsin at various 
time points and cell suspensions were then counted by flow cytometry using the True 
Volumetric Absolute Counting technique (Partec Instruments). 
 
Osteoclastogenesis assay 
Experiments were conducted as described previously (8,36), using murine 
bone marrow cells cultured in the presence of M-CSF (20 ng/mL) (R&D Systems) 
and RANK-L (30 ng/mL) (PeproTech), alone or in the presence of conditioned 
medium from transfectants (25 µg/mL). After 7 days in culture, mature osteoclasts 
ZHUHHQXPHUDWHGXQGHUDPLFURVFRSHRQWKHEDVLVRIWKHQXPEHURIQXFOHLWKUHH
nuclei) and on the tartrate-resistant acid phosphatase (TRAP) activity. Results were 
expressed as the number of osteoclasts per well. 
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Osteoblastogenesis assay 
Experiments were conducted as previously described (37). Briefly, MC3T3-E1 
osteoblastic cells were seeded in 12-well plates (105 cells/well) and cultured in 
DMEM medium containing 10% FBS and 50 Pg/mL ascorbic acid from day 1 to day 
8, at which time 10 mM E-glycero-phosphate (Sigma-Aldrich) was added to the 
culture medium and cells were further cultured with or without conditioned medium 
from transfectants (25 Pg/mL protein). At day 21, bone mineralized nodules were 
fixed and stained with von Kossa staining. Alternatively, nodules were harvested in 
lysis buffer for RNA extraction.  
 
Animals 
Four-week-old female BALB/c nude mice were purchased from Janvier 
Laboratories (Saint-Berthevin, France). Animals were maintained in a 12-h light-dark 
cycle and given free access to food and water. All procedures involving animals, 
including housing and care, the method by which they were sacrificed, and 
experimental protocols were conducted in accordance with approval of Ethical 
Committee (CEEA-55 &RPLWpG¶(WKLTXHHQ([SpULPHQWDWLRQ$QLPDOH) under project 
licence DR2016-15, University Claude Bernard Lyon-1.  
 
Animal studies 
Tumor xenograft experiments were conducted as previously described (8,36). 
Female Balb/c nude mice were inoculated subcutaneously with MDA-B02 
transfectants (106 cells in 50-ȝL PBS). Tumor size was calculated by external 
measurement of the width (m1) and length (m2) of tumor xenografts using a Vernier 
caliper. Tumor volume (TV) was calculated using the equation TV=(m12×m2)/2. At the 
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end of the protocols, mice were sacrificed and tumors collected, then prepared for 
immunohistochemistry. 
Bone metastasis experiments were conducted, as described previously (8,32). 
Transfectants (5 x 105 cells in 100 ȝ/ 3%6 ZHUH LQMHFWHG LQWR WKH WDLO DUWHU\ RI
anesthetized nude mice. Radiographs of anesthetized animals were taken weekly 
using a MX-20 cabinet X-ray system (Faxitron X-ray Corporation, Wheeling, IL). 
Osteolytic lesions were identified on radiographs as radiolucent lesions in the bone. 
The area of osteolytic lesions was measured using a computerized image analysis 
system, and the extent of bone destruction per leg was expressed in square 
millimeters. For measurement of skeletal tumor burden, bioluminescence imaging of 
animals was performed weekly using the Nightowl imaging system (Berthold, 
Germany). On day 32 after tumor cell inoculation, anesthetized mice were sacrificed 
by cervical dislocation after radiography and bioluminescence imaging.  
 
Bone histology, histomorphometry and immunohistochemistry 
Bone histology and histomorphometric analysis of bone tissue sections were 
performed as previously described (8,36). The bone volume (BV)/tissue volume (TV) 
and tumor volume (TuV)/soft tissue volume (STV) ratios represent the percentages of 
bone and tumor tissue, respectively. The in situ detection of osteoclasts was 
performed on TRAP-stained longitudinal paraffin-embedded medial sections of tibial 
metaphysis, using a commercial kit (Sigma). The resorption surface (Oc.S/BS) was 
calculated as the ratio of TRAP-positive trabecular bone surface (Oc.S) to the total 
bone surface (BS) using the image analysis system MorphoExpert (Explora-nova). 
For immunohistochemistry, tumor tissue sections were incubated with a 
mouse anti-human Ki-67 monoclonal antibody (DakoCytomation) or a rabbit 
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polyclonal anti-CD31 antibody (AnaSpec) that specifically recognize proliferative cells 
and blood vessels, respectively. The mitotic index and tumor microvessel density 
were quantified, as previously described (8).  
 
Statistical Analysis 
All data were analyzed using GraphPad Prism 5 software (version5.2; 
GraphPad Software, San Diego). Pairwise comparisons were carried out by 
performing nonparametric Mann-Whitney U test, one-way ANOVA, post-hoc 
Bonferroni test and Student¶V t-test, as indicated in figures and tables.  All tests were 
two-sided, and P values less than 0.05 were considered statistically significant. 
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Results  
MiR-30s are down-regulated in human osteotropic breast cancer cell lines, and 
their low expression levels in primary breast tumors are associated with poor 
relapse-free survival in patients  
We compared the miRNA expression profile of human MDA-MB-231 breast 
cancer cells with that of MDA-B02, a cell subpopulation which was previously 
selected in vivo on the basis of its high and selective capacity to colonize bones in 
mice (32), and of BC-M1, a breast cancer cell line which was established from DTCs 
in the bone marrow of a patient with no sign of metastasis at the time of surgery (33). 
A total of 152 miRNAs were significantly up- or down-regulated in these three breast 
cancer cell lines (Fig. 1A). For example, expression levels of miR-200 family 
members (miR-200a, miR-200b, miR-200c and miR-429) and of miR-138 and miR-
204, two metastasis-suppressing miRNAs, were markedly reduced in MDA-B02 and 
BC-M1 cells, compared to MDA-MB-231 cells (Fig. 1A). This was in agreement with 
the mesenchymal phenotype of these osteotropic cell lines that highly expressed 
CD44 and were CD24 negative (Supplementary Fig. S1). This difference was 
accompanied by increased expression of EMT-inducing transcription factors ZEB1, 
ZEB2, SNAI1 (snail) and SNAI2 (slug) and of mesenchymal markers N-cadherin and 
vimentin, whereas MDA-B02 and BC-M1 cells lost the expression of the epithelial 
marker E-cadherin (Supplementary Fig. S1). Of note, hierarchical clustering also 
showed that the expression levels of miR-30 family members were markedly down-
regulated in MDA-B02 and BC-M1 cells, compared to that observed in MDA-MB-231 
cells (Fig. 1A).  
To determine the role of the miR-30 family members in breast cancer bone 
metastasis, we first assessed the expression levels of miR-30s in human breast 
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cancer cell lines by quantitative RT-PCR. The levels of each miR-30 family member, 
including miR-30a-5p to miR-30e-5p and miR-30a*, miR-30d* and miR-30e* (also 
known as miR-30a-3p, miR-30d-3p, and miR-30e-3p), were substantially decreased 
in MDA-B02 and BC-M1 breast cancer cells, compared to MDA-MB-231 cells (Fig. 
1B). All of the luminal [estrogen receptor (ER)-positive and/or progesterone receptor 
(PR)-positive] breast cancer cell lines studied (T47-D, MCF-7, BT-474, and ZR-75-1) 
had moderate-to-strong miR-30s expression levels, compared to basal MDA-MB-231 
and MDA-B02 breast cancer cells (Supplementary Fig.S2). In basal Hs-578T cells, 
miR-30b and miR-30c expression levels were low, whereas expression levels of 
other miR-30 members were as high as in luminal breast cancer cells. MiR-30s 
expression levels in epidermal growth factor receptor2 (HER2)-positive SKBR3 cells 
(which are ER- and PR-negative) were high compared to that observed with HER2-
positive BC-M1 cells (Supplementary Fig. S2). However, there was a general trend 
towards high miR-30s expression levels in ER- and/or PR-positive breast cancer 
cells (Supplementary Fig. S2). This was confirmed by measuring absolute amounts 
of miR-30s in MCF-7 and MDA-B02 cells: these amounts in MCF-7 cells were 3 to 8-
fold higher than in MDA-B02 cells (Supplementary Fig. S3). Overall, these data were 
in line with a previous report showing that miR-30a and miR-30e are more expressed 
in luminal than basal breast cancer samples (38). Compared to MDA-MB-231 cells, 
the low miR-30s expression levels in osteotropic MDA-B02 and BC-M1 cells was 
explained, at least in part, by a defect in the miRNA biogenesis machinery, as 
exemplified by the decreased mRNA expression of Dicer (Fig. 1C), a type-III RNase 
involved in the processing of pre-miRNAs into mature miRNAs (6).  
 To determine whether miR-30s expression in tumors has a prognostic value, 
we analyzed by qRT-PCR the expression levels of miR-30a, miR-30b, miR-30c, miR-
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30d, miR-30e and let-7c in primary tumors of 109 breast cancer patients for whom 
there was no previous treatment and no evidence of distant metastasis at the time of 
diagnosis (35). Let-7c was used as a control for its well-known tumor suppressor role 
(39). Low miR-30s expression levels were significantly associated with DWXPRUVL]H
20 mm, a high grade and ER/PR-negative tumors (Supplementary Table S2). 
Additionally, low miR-30a and miR-30e expression levels in tumors were associated 
with patients having positive lymph nodes. Let-7c was inversely correlated with tumor 
size, confirming its tumor suppressor role (39). We next calculated the univariate Cox 
proportional hazard regression model for distant relapse-free survival (RFS) based 
on expression levels of miR-30 family members (30a, 30b, 30c, 30d, and 30e) and 
let-7c (used here as negative control). We found that low expression levels of miR-
30a, miR-30d and miR-30e were poor prognostic factors for RFS (Supplementary 
Table S3). There was also a trend, although not statistically significant (P = 0.068), 
towards an association of low miR-30b expression levels with poor RFS 
(Supplementary Table S3). MiR-30c and let-7c did not have a prognostic role for RFS 
(P = 0.223 and 0.279, respectively) (Supplementary Table S3). These data 
collectively suggested the clinical importance of miR-30s in human breast cancer and 
metastasis. 
 
MiR-30s impede tumor progression and bone destruction in an experimental 
model of human breast cancer bone metastasis 
 To study the function of miR-30s in bone metastasis, ER-/PR-negative MDA-
B02 cells were transduced by the retroviral vector pmiRVec containing different 
combinations of the five miR-30 genomic sequences downstream of a CMV promoter 
(see Supplementary Methods). Of note, stable overexpression of miR-30b-d or miR-
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30b-c in MDA-B02 cells did not modify expression levels of other members of the 
miR-30 family (Supplementary Fig. S4).  
 To determine whether miR-30s play a causal role in bone metastasis, parental 
MDA-B02 (MDA-B02-wt), mock-transduced MDA-B02 (MDA-B02-pmiRVec) or miR-
30s-overexpressing MDA-B02 cells (MDA-B02-pmiR30b-d, MDA-B02-pmiR30b-c, or 
MDA-B02-pmiR30a-b-c-d-e) were injected into the tail artery of immunodeficient 
mice. Using this animal model, radiographic analysis on day 32 after tumor cell 
injection revealed that the extent of osteolytic lesions in animals bearing MDA-B02-
pmiR30a-b-c-d-e tumors was 2- to 2.5-fold lower than that of animals bearing 
pmiRVec- or MDA-B02-wt-tumors (Table 1 and Fig. 2A). Bioluminescence imaging 
indicated that there was also a reduction of tumor burden in hind limbs of animals 
bearing MDA-B02-pmiR-30a-b-c-d-e tumors, compared to that observed with MDA-
B02-wt and MDA-B02-pmiRVec tumor-bearing animals (Fig. 2B). Histomorphometric 
analysis of hind limbs with metastases from animals bearing miR-30s tumors showed 
that the BV/TV ratio (a measure of the bone volume) was substantially increased, 
compared with pmiRVec-tumor-bearing animals (Table 1 and Fig. 2C). This 
difference was accompanied by a sharp reduction in the TuV/STV ratio (a measure of 
the skeletal tumor burden) in miR-30s tumor-bearing animals, compared with 
pmiRVec-tumor-bearing animals (Table 1 and Fig. 2C). Additionally, there was a 
decrease in the TRAP staining of bone tissue sections of metastatic legs from miR-
30s tumor-bearing animals (indicating a decrease of active-osteoclast resorption 
surfaces), compared with pmiRVec-tumor-bearing animals (Table 1 and Fig. 2D). 
Similar results were obtained with MDA-B02 cells overexpressing miR-30b-d or miR-
30b-c (Table 1). Overall, these data indicated that miR-30s inhibit breast cancer bone 
metastasis. 
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MiR-30s restore the balance between bone resorption and bone formation 
 Tumor cells promote bone destruction through the production of factors that 
stimulate osteoclast formation and repress osteoblast formation, resulting in an 
imbalance between bone resorption and bone formation (1,3). After having observed 
that miR-30s overexpression in MDA-B02 cells inhibited bone destruction in animals 
(Table 1 and Fig. 2), we then asked whether miR-30s had any influence on 
osteoclast differentiation. We treated primary mouse bone marrow cell cultures with 
RANKL and M-CSF together with the conditioned medium from MDA-B02 cells 
transfected with a mix of the five miR-30s-5p mimics at equimolar concentrations 
(MDA-B02-miR-30s) or by equivalent concentrations of a negative control miR 
scramble sequence (MDA-B02-Ctrl). Consistent with in vivo data (Fig. 2D and Table 
1), the conditioned medium from MDA-B02-miR-30s cells decreased the formation of 
TRAP-positive multinucleated osteoclasts, compared with that of MDA-B02-Ctrl cells 
(316 ± 29 vs 416 ± 8 osteoclasts/well; n=3; P < 0.001) (Fig 3A). This inhibitory effect 
of the conditioned medium from MDA-B02-miR-30s cells on osteoclastogenesis was 
accompanied by a decreased expression of Trap (a marker associated with 
osteoclast differentiation) and Ctsk (an osteoclast-derived cysteine protease enabling 
degradation of the collagenous matrix) in osteoclasts (Fig. 3B). The expression levels 
of other markers associated with osteoclast differentiation (e.g., Car2, Cfms, ATP6v) 
and cytoskeleton morphology (e.g., Itgb3) were not affected (Fig. 3B). MDA-B02 cells 
secrete cytokines and interleukins known to stimulate osteoclast activity (IL-8, IL-11, 
MCP-1) (36). Compared to MDA-B02-Ctrl cells, miR-30s overexpression in MDA-B02 
cells inhibited IL-8, IL-11 and TWF1 (twinfilin1), an upstream regulator of IL-11 
expression (26) (Fig. 3B). Additionally, the inhibitory effect of miR-30s on IL-8 and IL-
11 expression was validated by ELISA, demonstrating a reduced production of these 
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interleukins in the conditioned medium of MDA-B02-miR-30s cells, compared with 
that of MDA-B02-Ctrl cells (193 ± 80 vs 375 ± 70 pg/ml and 345 ± 219 vs 821 ± 345 
pg/ml, respectively; n=3; P < 0.05).  
 We next investigated whether miR-30s expression in MDA-MB-B02 cells could 
also influence osteoblastogenesis (Fig. 3C). The conditioned medium from MDA-
B02-Ctrl cells inhibited the formation of bone nodules and their mineralization, 
compared to untreated osteoblasts (Fig. 3C). By contrast, the conditioned medium 
from MDA-B02-miR-30s cells significantly reversed the inhibitory effect on osteoblast 
differentiation (Fig. 3C) and increased the expression of markers associated with 
osteoblast differentiation (Alp, Ocn) (Fig. 3D). Interestingly, however, the direct 
transfection of MC3T3-E1 osteoblasts with the five miR-30 mimics at equimolar 
concentrations induced a strong inhibition of osteoblastogenesis (Fig. 3E). These 
findings were in agreement with a previous study (16) showing that miR-30s 
negatively regulate osteoblast differentiation. Thus, our results demonstrated that 
miR-30 mimics used to transfect MDA-B02 cells were not secondarily released into 
the conditioned medium of transfected cells. Osteoblast differentiation would have 
been otherwise inhibited. Instead, miR-30 mimics mediated translational repression 
of specific mRNAs, which was followed by a decreased secretion of proteins by 
MDA-B02-miR-30s cells that, in turn, negatively regulated osteoblastogenesis. In this 
respect, we found that miR-30 mimics inhibited DKK-1 in MDA-B02 cells, whereas 
the expression of other osteoblast differentiation inhibitors (NOG, SOST) remained 
unaffected (Fig. 3F). 
 Collectively, the above data indicate that miR-30s act in tumor cells by 
decreasing the production of osteoclast differentiation stimulators (IL-8, IL-11) and 
osteoblast differentiation inhibitors (DKK-1) which, in turn, partially restores the 
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balance between bone resorption and bone formation, leading to a reduction of bone 
destruction in vivo. 
 
MiR-30s reduce primary breast cancer outgrowth in vivo by inhibiting tumor 
cell invasion 
 We observed that miR-30s overexpression reduces bone destruction and 
skeletal tumor burden in animals (Fig. 2 and Table 1). As bone is resorbed, bone-
derived growth factors that are stored in the bone matrix are released and stimulate 
tumor growth (1,3). In order to be free from the impact of growth factors released 
from resorbed bone that stimulate skeletal tumor outgrowth, we investigated the role 
of miR-30s in breast cancer cell growth using in vivo experiments in which MDA-B02 
cells overexpressing miR-30b and -30d (MDA-B02-pmiR30b-d) and their control 
counterparts (MDA-B02-pmiRVec) were implanted subcutaneously in animals. Tumor 
outgrowth did not differ between groups until day 35 after tumor cell inoculation, 
indicating that miR-30b and -30d did not interfere with tumor take. However, MDA-
B02-pmiR30b-d tumors grew more slowly afterwards, resulting in a significantly lower 
tumor volume at day 50 after tumor cell inoculation, compared to MDA-B02-pmiRVec 
tumors (Fig. 4A). Immunostaining of tumor xenografts with an anti-CD31 antibody 
that specifically recognizes murine endothelial cells showed that miR30b-d 
overexpression was associated with decreased vascularization of MDA-B02-
pmiR30b-d tumors compared with MDA-B02-pmiRVec tumors (Fig. 4B). The 
proliferative index of MDA-B02-pmiR30b-d tumors, as judged by Ki67 
immunostaining, was also decreased compared with MDA-B02-pmiRVec tumors 
(Fig. 4C). However, miR30b-d overexpression or the use of synthetic miR-30 mimics 
did not affect MDA-B02 cell proliferation in vitro (Figs. 4D and 4E). By contrast, MDA-
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B02 cell invasion was similarly negatively affected by the stable overexpression of 
miR-30b-d, miR-30b-c or miR-30a-b-c-d-e (Fig. 4F). Additionally, the treatment with 
antagomiRs of MDA-B02 cells stably transduced with the different genomic 
sequences of miR-30s restored the invasiveness properties of these cells (Fig. 4G). 
The transfection of MDA-B02 or BCM-1 cells with equimolar concentrations of miR-
30 mimics (miR-30a-b-c-d-e) also inhibited tumor cell invasion compared to their 
respective control counterparts (Fig. 4H). Thus, these data indicate that miR-30s 
inhibit breast cancer cell invasion, providing an explanation for tumor growth 
reduction. 
 
MiR-30s directly target multiple genes associated with bone metastasis 
formation, including targets such as CDH11, ITGA5 and ITGB3  
 To identify direct miR-30s target mRNAs, we first used a publically available 
miRNA target prediction program (Targetscan) and then performed experimental 
validation analyses. The online target gene prediction analysis allowed us to identify 
¶-UTR putative direct binding sites for miR-30s that we then narrowed to 53 genes 
on the basis of their involvement in signaling pathways associated with bone 
metastasis (Supplementary Table S4). Among these, we identified the transcription 
factor RUNX2, which was previously reported to be a direct target for mir-30c (17). 
Beside RUNX2, we found that miR-30s reduced the expression of several other 
osteomimetic genes (CDH11, CX43, DKK1) in MDA-B02 and BC-M1 breast cancer 
cells (Supplementary Fig. S5). As aforementioned, miR-30s also inhibited the 
expression of genes associated with osteoclastogenesis, such as IL-8, IL-11 and 
TWF1 (twinfilin1), an upstream regulator of IL-11 expression (26) (Fig. 3B and 
Supplementary Fig. S5). They also inhibited the expression of integrins (ITGA5, 
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ITGB3) and connective tissue growth factor (CTGF) (Supplementary Fig. S5). Of 
note, we confirmed by western blotting analysis that there was a moderate-to-strong 
inhibition of the expression of these miR-30 targets at the protein level 
(Supplementary Fig. S6). 
We then focused our attention to CDH11. Interestingly, as opposed to the majority of 
genes for which miR-V ELQG WR WKH ¶-UTR of target mRNAs, the miRNA:mRNA 
alignment analysis showed that a conserved 8-mer site in the open reading frame 
(ORF) of CDH11 matched the seed region of the five miR-30 family members 
(Supplementary Fig. S7). The homology test showed that this binding site for miR-
30s was evolutionary conserved among various vertebral species and that the 
thermodynamic stability of the base pairing duplexes was compatible with efficient 
inhibition of CDH11 expression (Supplementary Fig. S7). In agreement with these 
observations, there was a stark reduction of CDH11 protein levels in MDA-B02 cells 
transfected with miR-30s, compared to MDA-B02-ctrl cells (Fig. 5A). To validate a 
direct targeting of CDH11 by miR-30s, HEK-293T cells overexpressing or not 
overexpressing miR-30s were transiently transfected with the psiCHECK-2 vector in 
which was cloned the ORF of CDH11 containing the wild type or mutated conserved 
binding site for miR-30s. As shown in Fig. 5B, luciferase expression only decreased 
when HEK-293T cells overexpressing miR-30s were transfected with wild-type ORF-
CDH11 vector, indicating that the 8-mer binding site for miR-30s in the ORF of 
CDH11 was functional. Similarly, following transient transfection of MDA-B02-ctrl, 
MDA-B02-pmiR-30a-b-c-d-e and MDA-MB-231 cells with the psiCHECK-2-ORF-
CDH11 vector, luciferase expression was only reduced in tumor cells overexpressing 
miR-30s (Supplementary Fig. S7). Thus, CDH11 is a direct target for repression by 
miR-30s. To further validate the role of CDH11, we then examined whether the 
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silencing of CDH11 expression in MDA-B02 cells would repeat the inhibitory effect of 
miR-30s on bone metastasis formation. Compared to MDA-B02 control cells, 
cadherin-11 protein expression levels in MDA-B02-shCDH11 cells were reduced by 
>90% as analyzed by Western blotting (Fig. 5C). Additionally, as previously reported 
for prostate cancer cell interaction with osteoblasts (40), the silencing of CDH11 in 
luciferase-expressing MDA-MB-231, MDA-B02 and Hs578T cells also decreased 
breast cancer cell interaction to osteoblasts (Fig. 5D, and Supplementary Fig. S8). 
Moreover, CDH11 silencing in MDA-B02 cells drastically reduced bone metastasis 
burden in vivo (Fig. 5E). 
 Strikingly, a strong over-representation of genes associated with tumor cell 
adhesion and invasion (e.g., integrins D2E1, D5E1, D4E1 and DvE3, connective tissue 
growth factor) was also observed among miR-30s down-regulated genes 
(Supplementary Table S4). We found a conserved 8-PHUELQGLQJVLWHLQWKH¶875RI
integrin E3 (ITGB3) and of CTGF that matched with the seeding region of the five 
miR-30 family members (Supplementary Fig. S9). CTGF enhances the motility of 
breast cancer cells via an integrin-DvE3-dependent signaling pathway (41). In 
accordance with these results, CTGF was poorly expressed in MDA-MB-231 that 
contain high endogenous levels of levels of miR-30s and we observed a marked 
reduction of CTGF and ITGB3 expression in MDA-B02 cells stably transfected with 
the retroviral vector pmiRVec containing the five miR-30s (Supplementary Fig. S9). 
To validate the direct targeting of CTGF by miR-30s, HEK-293T cells overexpressing 
or not overexpressing miR-30s were transiently transfected with the luciferase 
reporter psiCHECK- YHFWRU LQ ZKLFK ZDV FORQHG WKH ¶875 RI CTGF containing 
either the wild type or mutated sequence of the conserved binding site for miR-30s. 
As shown in Supplementary Figure S9, miR-30s significantly decreased relative 
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luciferase activity in HEK-293T cells overexpressing miR-30s compared to their 
control counterparts. By contrast, luciferase activity was not decreased when HEK-
293T cells overexpressing miR-30s were transfected wLWK PXWDWHG ¶875 &7*)
vector (Supplementary Fig. S9), indicating that the 8-mer binding site was functional.  
 Among putative integrin targets for miR-30s (supplementary Table S4), ITGA5 
was identified as being a novel direct target for repression by miR-30s. The 
miRNA:mRNA alignment analysis showed that a conserved 8-PHUVLWHLQWKH¶875
of ITGA5 matched the seed region of the five miR-30 family members 
(Supplementary Fig. S10). Transient transfection of HEK-293T cells overexpressing 
miR-30s with the psiCHECK-2-wild-W\SH ¶875-ITGA5 vector led to a decrease in 
OXFLIHUDVHDFWLYLW\ZKHUHDVWUDQVIHFWLRQZLWKWKHPXWDWHG¶875-ITGA5 vector had no 
inhibitory effect (Fig. 6A). Thus, the 8-mer binding site for miR-V LQ WKH¶875RI
ITGA5 was functional. In addition, transfection of MDA-B02 and BC-M1 cells with 
miR-30 mimics caused a moderate-to-strong reduction of ITGA5 protein levels (Fig. 
6B). To further validate the role of ITGA5, we then examined whether the silencing of 
ITGA5 expression in Hs-578T cells (a triple negative breast cancer cell line 
expressing high ITGA5 levels) would recapitulate the inhibitory effect of miR-30s on 
bone metastasis formation. Compared to Hs-578Tluc2 control cells, ITGA5 protein 
expression levels were drastically reduced in ITGA5-silenced Hs-578Tluc2 cells as 
analyzed by Western blotting (Fig. 6C). Moreover, the silencing of ITGA5 in 
luciferase-expressing Hs-578Tcells led to a substantial reduction of bone metastasis 
burden in vivo (Fig. 6D).   
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Discussion 
Our study establishes that miR-30 family members (miR-30a, miR-30b, miR-
30c, miR-30d and miR-30e) act as tumor suppressor genes in breast cancer bone 
metastasis. Specifically, we showed that miR-30s reduce breast cancer cell invasion, 
osteomimicry and bone destruction in vivo by targeting multiple bone metastasis-
associated genes, including CTGF, ITGB3, ITGA5, IL-8, TWIF1/IL-11, DKK-1, 
RUNX2 and CDH11 (Fig. 6E). This inhibitory effect of miR-30s on breast cancer 
bone metastasis formation was the same, whether tumor cells overexpressed miR-
30b/d, miR-30b/c or the whole miR-30 family. Although miR-30 family members 
H[SUHVVGLIIHUHQW¶FRPSOHPHQWDU\VHTXHQFHVWKH\all share the same ¶seed 
sequence and, therefore, act through common targets to reduce skeletal tumor 
burden and block tumor-driven osteolytic lesions. Similarly, Zhang et al. reported that 
there is no additive effect of the whole family of miR-30s on inhibition of metadherin 
(MTH) expression in human breast cancer cells, compared to miR-30a alone (22). 
The reason behind overexpressing pairs of some miR-30 family members was to 
investigate specific traits of miR-30 biology. During miRNA biogenesis, pre-miRNAs 
are exported in the cytoplasm as miRNA:miRNA* duplexes, which are processed by 
Dicer and then they associate with Argonaute proteins to form a complex (42). Only 
the mature miRNA (miRNA-5p) is retained in the complex, while the other strand of 
the duplex (miRNA* or miRNA-3p) is degraded (42). However, miRNA-3ps can be 
thermodynamically stable and bind to mRNAs, suggesting they could play a 
cooperative role with miRNA-5ps by targeting the same mRNA (43). In our study, we 
showed that MDA-MB-231, MDA-B02 and BC-M1 cells expressed both strands for 
miR-30a, miR-30d and miR-30e, whereas only the mature miRNA-5p was expressed 
for miR-30b and miR-30c (Fig. 1B). The reduction of bone metastasis burden in vivo 
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was however the same whether MDA-B02 cells overexpressed miR-30b/c or miR-30-
a-b-c-d-e (Table 1), thereby indicating that only the mature miRNA-5p strands of 
miR-30s were responsible for inhibition of bone metastasis. The inhibitory effect of 
miR-30b and miR-30c would have been otherwise lower than that of miR-30-a-b-c-d-
e. We overexpressed miR-30b and miR-30d in breast cancer cells because this pair 
of genes is in cluster on the same chromosome (16). We surmised that they might be 
coordinately involved in the regulation of bone metastasis formation. Overexpression 
of miR-30b/d did not however function more efficiently than miR-30b/c and miR-30-a-
b-c-d-e to inhibit osteolysis (Table 1). Overall, our results are in line with previous 
experimental findings showing that miR-30 family members suppress primary tumor 
growth and soft tissue metastasis (lung, liver) in different animal models of cancer 
(breast, colon, liver, osteosarcoma, thyroid) (19-27,31). However, to the best of our 
knowledge, this is the first time the contribution of miR-30 family members in bone 
metastasis is reported. 
Breast cancer cells promote bone destruction through the production of factors 
that stimulate osteoclast formation (e.g., IL-8, IL-11, MCP-1) and repress osteoblast 
formation (e.g., DKK-1, SOST, noggin), resulting in an imbalance between bone 
resorption and bone formation (1,3,36). Here, we show that miR-30s inhibited the 
expression of osteoclast differentiation stimulators IL-8 and IL-11 and reduced their 
protein levels. Additionally, the expression of TWF1, an upstream regulator of IL-11, 
was inhibited, which was in agreement with a previous finding (26) showing that miR-
30c suppresses IL-11 expression through inhibition of TWF1. Other miRNAs (miR-
204, miR-211 and miR-379), whose expression is down-regulated in highly MDA-MB-
231 bone metastatic variants, have been identified as potent inhibitors of 
transforming growth factor-E-induced IL-11 secretion (17). Beside inhibition of bone 
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resorption, we show that miR-30s reduced the expression of the osteoblast 
differentiation inhibitor DKK-1 in breast cancer cells. SOST is another osteoblast 
differentiation inhibitor in breast cancer cells whose expression is inhibited by miR-
218 (44). Collectively, these data indicate that miR-30s, as well as other miRNAs 
(miR-204, miR-211, miR-218 and miR-379), are capable of restoring bone 
homeostasis, thereby impairing breast cancer-induced bone destruction in vivo.  
Tumor cells can adapt to the bone microenvironment by expressing genes that 
are normally expressed by osteoblasts and osteoclasts (10,14,15,36). Here we 
focused our attention on CDH11 because (i) it is the archetype of osteoblast 
differentiation, and (ii) previous studies have revealed its crucial role in breast and 
prostate cancer bone metastasis formation by promoting tumor cell invasion and 
interactions with osteoblasts (40,45,46). We found that CDH11 is a novel direct target 
for repression by miR-30s. Moreover, CDH11 silencing in breast cancer cells 
recapitulated inhibitory effects of miR-30s on skeletal tumor burden in vivo (Fig. 5). 
Interestingly, miR-30s bound directly in the coding region of CDH11. It has been 
proposed that the direct targeting of miRNAs to the coding region may speed up the 
silencing of stable mRNAs (47). Other miRNAs (miR-135, miR-203 and miR-218) 
have been reported to inhibit SOST and RUNX2 expression in breast cancer cells, 
which are two other osteoblastic genes associated with tumor cell osteomimicry 
(44,48). Thus, the dysregulation of miR-30s and other microRNAs (miR-135, miR-
203, miR-218) in breast cancer cells enhances abnormal expression of osteoblast-
specific genes (CDH-11, RUNX2, DKK-1, SOST), which endows tumor cells with full 
competence for outgrowth in the bone marrow. 
Among genes that are down-regulated by miR-30s, we observed a strong 
over-representation of genes associated with tumor cell adhesion and invasion. Of 
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note, ITGA5 was identified as a novel direct target for repression by miR-30s. ITGA5 
mediates breast cancer cell adhesion and migration, which results in lymph node and 
lung metastasis formation in animal models (49,50). ITGA5 has been also identified 
as a transcriptional target of RUNX2 (51). Its role in bone metastasis formation was 
however unknown. Here, we show that the silencing of ITGA5 in triple negative 
breast cancer cells recapitulated the inhibitory effect of miR-30s on bone metastasis 
formation in vivo, suggesting that this integrin could be an interesting target for 
therapeutic intervention in bone metastasis. This hypothesis clearly warrants further 
investigation. Two additional genes, CTGF and ITGB3, which are involved in bone 
metastasis formation, were also identified as direct miR-30 targets. CTGF is a pro-
invasive and angiogenic factor that enhances the motility of breast cancer cells via an 
ITGB3-dependent signaling pathway and it promotes the formation of osteolytic 
lesions in animals (3,41,52). ITGB3 confers on breast cancer cells a greater 
propensity to metastasize to bone (32,53). We found conserved binding sites in the 
¶875RICTGF and ITGB3 that matched with the seeding region of the five miR-30 
family members. These findings were in agreement with previous reports showing 
that CTGF and ITGB3 are direct targets for miR-30a and miR-30c in colorectal 
cancer cells and cardiomyocytes, respectively (17,54). In addition, miR-30a inhibits 
invasiveness of breast and colorectal cancer cells in vitro (17, 22), which is in 
agreement with our study.  
The main limitation of our study is that experimental bone metastases were 
conducted using triple negative breast cancer cells, whereas ER-positive breast 
cancers are prone to metastasize to bone. All of the ER-positive breast cancer cell 
lines studied (T47D, MCF-7, BT-474, and ZR-75-1) had moderate-to-high miR-30s 
expression levels, compared to triple negative MDA-B02 and BC-M1 breast cancer 
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cells (Supplementary Figs S2 and S3). In an attempt to better reflect bone metastasis 
from human breast cancer, we therefore transfected ER-positive MCF-7 cells with 
antagomiR-30s to induce a functional blockade of miR-30s. However, antagomiR-30s 
did not modulate MCF-7 cell migration and invasion in vitro and did not interfere with 
MCF-7 cell bone marrow colonization in vivo (Supplementary Fig. S11). Thus, our 
results only apply to triple negative breast cancer.  
In conclusion, our findings show that miR-30s employ multiple mechanisms to 
impede breast cancer bone metastasis, reducing tumor cell invasion, osteomimicry 
and bone destruction in vivo by directly targeting multiple genes. Some of these 
genes may represent attractive targets for developing new therapeutic strategies in 
the management of bone metastasis associated with triple negative breast cancer. 
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Table 1. miR30s overexpression in MDA-B02 breast cancer cells decreases cancer-induced osteolytic lesions in animals.a 
Cell line  Radiography Histomorphometry TRAP staining 
 
mm2/mouse P BV/TV (%) P TuV/STV (%) P OC.S/BS (%) P 
MDA-B02-wt 13 ± 1.1 (n=8) ns       
MDA-B02-pmirVec 14.1 ± 1.7 (n=10) - 11.9 ± 2.4 (n=13) - 45.2 ± 5.4 (n=13) - 77.4 ± 8.1 (n=5) - 
MDA-B02-pmir-30b-d 7.7 ± 1.2 (n=9) 0.01 20.9 ± 5.3 (n=5) 0.01 14.7 ± 5.6 (n=5) 0.02 60.3 ± 2.2 (n=5) 0.05 
MDA-B02-pmir-30b-c 6 ± 0.96 (n=7) 0.01 27.6 ± 2.7 (n=5) 0.01 24.7 ± 2.5 (n=5) 0.02 48 ± 1.5 (n=4) 0.01 
MDA-B02-pmir30a-b-c-d-e 5.7 ± 0.8 (n=6) 0.02 26.6 ± 2.7 (n=4) 0.02 21.8 ± 6.1 (n=4) 0.05 41.7 ± 16.5 (n=4) 0.02 
a
 All measurements were made 32 days after tumor cell inoculation. P values (two-sided) are for pairwise comparisons with MDA-B02-pmirVec 
control group using the Mann-Whitney U test. BV/TV: bone volume-to-tissue volume ratio. TuV/STV: tumor volume-to-soft tissue volume ratio. 
TRAP: tartrate-resistant acid phosphatase. OC.S/BS: active osteoclast resorption surface-to-bone surface. - : not applicable (referent). 
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Figure legends 
Figure 1: MiRNA profiling of human MDA-MB-231 breast cancer cells with that of 
osteotropic MDA-B02 and BC-M1 breast cancer cells. (A) Heat map diagram with 
two-way hierarchical clustering of miRNAs and breast cancer cell lines. Each row 
represents a miRNA and each column represents a breast cancer cell sample. The 
color scale at the bottom illustrates the relative expression level of each miRNA 
across all samples: red and green are expression levels above and below the mean, 
respectively. Black is the mean expression level. MiR-30 family members are shown 
in red boxes. Metastasis-suppressing miRNAs, which are relevant to EMT and 
cancer cell stemness, are indicated by red arrows. Values are representative of the 
relative quantification of miRNAs measured by TaqMan Low Density Array in three 
separated cell cultures. 'Ct values were calculated using RNU48 and Snu6, as 
endogenous controls with the RQ manager (Applied Biosystems). (B) qRT-PCR 
analysis of miR-30-a,-b,-c,-d,-e and miR-30-a*, -d*, -e* expression levels in MDA-B02 
and BC-M1 cells compared to MDA-MB-231 cells. Data are the mean ± SD of 3 to 4 
independent experiments. Using one-way analysis of variance, miR-30s expression 
levels in MDA-B02 and BC-M1 cells were statistically significantly different (P < 
0.0001) from that of MDA-MB-231 cells. (C) qRT-PCR analysis of Dicer mRNA 
expression levels in MDA-B02 and BC-M1 cells, compared to MDA-MB-231 cells. 
Results are the mean ± SD of 3 independent experiments. Statistical analysis was 
performed using two-sided 6WXGHQW¶VW-test. **, ***: P < 0.01 and 0.001, respectively.  
Figure 2: miR-30s overexpression in breast cancer cells reduces the extent of 
osteolytic lesions and skeletal tumor burden in metastatic animals. (A) 
Representative radiographs of hind limbs with osteolytic lesions (arrows) from female 
Balb/c nude mice bearing breast tumors at day 32 after tumor cell inoculation. MDA-
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B02-wt: parental cells; MDA-B02-pmiRVec: mock-transfected cells; MDA-B02-pmiR-
30a-b-c-d-e: miR30s-overexpressing cells. (B) Representative whole body 
bioluminescence imaging of animals bearing MDA-B02-wt, MDA-B02-pmiRVec or 
MDA-B02-pmiR30a-b-c-d-e tumors at day 32 after tumor cell inoculation. (C) 
*ROGQHU¶V WULFKURPH staining of tissue sections of tibial metaphysis from tumor-
bearing animals. Bone is stained green, whereas bone marrow is stained violet and 
tumor cells (asterisk) are stained brown. (D) TRAP-stained metastatic bone tissue 
sections. Osteoclasts on bone surfaces are stained red (white arrows). The images 
shown are examples that best illustrate miR-V¶ HIIHFWV RQ inhibition of bone 
destruction and tumor burden. 
Figure 3: miR-30s restore bone homeostasis. (A) In vitro osteoclast differentiation of 
murine bone marrow cells treated with M-CSF+RANKL in combination with the 
conditioned medium (CM) of mock-transfected MDA-B02 cells (MDA-B02-Ctrl) or 
MDA-B02 cells overexpressing miR-30s (MDA-B02-miR-30s). Mature osteoclasts 
were quantified as multinucleated (more than 3 nuclei), TRAP-positive cells. 
Representative images are shown for each group. (B) Upper graphs: RT-qPCR 
analysis of murine osteoclasts treated with the CM from MDA-B02-Ctrl or MDA-B02-
miR-30s cells. Atp6v: V-ATPase; Car2: anhydrase carbonic; Cfms: Colony-
stimulating factor-1 receptor; Ctsk: cathepsin K; Itgb3: integrin beta-3; Mmp9: matrix 
metalloprotease 9; Trap: tartrate-resistant acid phosphatase. Lower graphs: RT-
qPCR analysis of MDA-B02-Ctrl and MDA-B02-miR-30s cells. IL-8: interleukin-8; IL-
11: interleukin-11; TWF1: twinfilin-1. (C) In vitro differentiation of osteoblastic MC3T3-
E1 cells cultured in osteogenic conditions with or without CM from MDA-B02-Ctrl or 
MDA-B02-miR-30s cells. Bone mineralized nodules stain black with von Kossa 
staining. (D) RT-qPCR analysis of MC3T3-E1 cells treated with the CM from MDA-
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B02-Ctrl or MDA-B02-miR-30s cells. Alp: alkaline phosphatase; Ocn: osteocalcin; 
Opg: osteoprotegerin; Opn: osteopontin; Rankl: receptor activator of nuclear factor 
kappa-B ligand; Runx2: Runt-related transcription factor 2. (E) In vitro differentiation 
of MC3T3-E1 cells cultured in osteogenic conditions, then left untreated or 
transfected with miR-30s mimics. (F) RT-qPCR analysis of MC3T3-E1 cells treated 
with the CM from MDA-B02-Ctrl or MDA-B02-miR-30s cells. Dkk-1: Dickkopf-related 
protein 1; Nog: noggin; Sost: sclerostin. For qRT-PCR analyses, data are the mean ± 
SD of 3 separate experiments. P values (two-sided) are for pairwise comparisons 
with the control group using the Mann-Whitney U test. *, **, ***:  P < 0.05, 0.02 and 
0.01, respectively. 
Figure 4: miR-30s reduce breast cancer outgrowth in vivo and tumor cell invasion in 
vitro. (A) MDA-B02-pmiRVec (control) and MDA-B02-pmiR-30b-d cells were 
inoculated subcutaneously in female Balbc nude mice. Tumor volumes were 
measured with a Vernier caliper. (B, C) CD31 and Ki-67 immunostaining of tissue 
sections of harvested tumors from mice inoculated with MDA-B02-pmiRVec and 
MDA-B02-pmiR-30b-d, as a measurement of the number of tumor-associated blood 
vessels and proliferative index of tumor cells, respectively. (D) Counting of MDA-B02-
pmiRVec and MDA-B02-pmiR-30b-d cells in culture as a function of time after cell 
plating. (E) MDA-B02 cells were transfected with miRNA mimics (30-b and- c; 10 nM 
each), (30-d and-b; 10 nM each), (30abcde; 10nM each) or scramble mimics (Scbl; 
50nM). Transfected cells in culture were enumerated as a function of time, 48-h after 
cell plating. (F) MDA-B02-pmiRVec, MDA-B02-pmiR-30b-d, MDA-B02-pmiR-30b-c 
and MDA-B02-pmiR-30abcde cells were loaded in inserts with a porous membrane 
coated with basement membrane Matrigel (upper chamber), and the chemoattractant 
(serum) was placed in wells of the companion plate (lower chamber). After 24-h 
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incubation at 37°C, the noninvading cells were removed and the invading cells on the 
under surface of the inserts were fixed, stained and counted under microscope. (G) 
Same as in (F) for MDA-B02 cells transduced with different genomic sequences of 
miR-30s and treated with their corresponding antagomiR-30s or a scramble 
antagomiR (negative control). Results were obtained after 48-h incubation at 37°C. 
(H) Same as in (F) for MDA-B02 and BC-M1 cells transfected with equimolar 
concentrations (10nM) of each miR-30 mimic or with 50nM of scramble mimic 
(negative control). In vivo and in vitro data are the mean ± SD of 3 separate 
experiments. P values (two-sided) are for pairwise comparisons with control group 
using unpaired 6WXGHQW¶Vt-test. 
Figure 5: Cadherin-11 (CDH11) is a direct target for repression by miR-30s. (A) 
Western blotting of CDH11 and D-tubulin in MDA-B02 cells transduced with different 
genomic sequences of miR-30s, compared to parental MDA-MB-231 cells. Tubulin 
was used as a control for equal loading. (B) Relative luciferase activity in HEK-293T 
cells overexpressing miR-30s (CDH11-wt-miR-30s and CDH11-mut-miR-30s) or not 
overexpressing miR-30s (CDH11-wt) that were transiently transfected with 
psiCheck2-CDH11 reporter vector containing either the wild-type (CDH11-wt, 
CDH11-wt-miR-30s) or mutated (CDH11-mut-miR-30s) binding site. Values are 
normalized to that of the internal firefly luciferase. Mean ± SD: n=3. (C) Western 
blotting of CDH11 and D-tubulin in parental MDA-B02 cells and MDA-B02 cells 
silenced for CDH11 (MDA-B02-sh-CDH11). (D) MDA-B02 and MDA-B02-sh-CDH11 
cell interaction with MC3T3-E1 osteoblasts as a function of time after cell plating. 
Mean ± SD, n=3. (E) CDH11 silencing in MDA-B02 reduced bone metastasis burden 
in vivo. Bioluminescence was analyzed in mice inoculated intra-arterially with MDA-
B02-Ctrl and MDA-B02-Sh-CDH11 cells (n=6 per group), 7 days after tumor cell 
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injection. For in vitro and in vivo experiments, P values (two-sided) are for pairwise 
comparisons with control group using the Mann-Whitney U test. *, **: P < 0.05 and 
0.02, respectively.  
Figure 6: Integrin alpha 5 (ITGA5) is a direct target for repression by miR-30s. (A) 
Relative luciferase activity in HEK-293T cells expressing miR-30s mimics (ITGA5-wt-
miR30s, ITGA5-mut-miR-30s) or a scramble mimic (ITGA5-wt-Scrbl) that were co-
transfected with the psiCheck2-ITGA5 reporter vector containing either the wild-type 
(ITGA5-wt-Scrbl, ITGA5-wt-miR30s) or mutated (ITGA5-mut-miR-30s) binding site. 
Values are normalized to that of the internal firefly luciferase. Mean ± SD, n=3. (B) 
Western blotting of ITGA5 and D-tubulin in MDA-B02 and BC-M1 cells after cell 
transfection with negative control scramble mimics (Ctrl) or miR-30s mimics (miR-
30s). Tubulin was used as a control for equal loading. (C) Western blotting for ITGA5 
expression in mock-transduced (Scrbl) and ITGA5-silenced Hs-578T breast cancer 
cells (ITGA5-silenced). Tubulin was used as a control for equal loading. (D) Left 
panels: Whole body bioluminescence imaging of animals at day 7 after intra-arterial 
inoculation of luciferase expressing Hs-578T cells that were previously mock-
transduced or silenced for ITGA5 expression. Right panel: graphs showing the 
percentage of metastatic animals in each group (5 to 8 animals per group). P < 
0.00001; P value (two-sided) is for pairwise comparison with mock-transduced cells 
using the Mann-Whitney U test. (E) Bone metastasis suppression by multiple miR-30 
regulatory networks. MiR-30s repress genes that are associated with osteomimicry, 
invasion and bone destruction, thereby inhibiting bone metastasis formation. CDH11: 
cadherin-11; CTGF: Connective Tissue Growth Factor; Dkk-1: Dickkopf-related 
protein 1; IL-8: interleukin-8; IL-11: interleukin-11; ITGA5: integrin alpha5; ITGB3: 
integrin beta3; Runx2: Runt-related transcription factor 2. 






